Peng Qiuwei, Wang Jian, Li Kesong, Xia Congming, Yao Chuanhui, Guo Qiuyan, Gong Xun, Tang Xiaopo, Jiang Quan
Department of Rheumatology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Front Pharmacol. 2025 Feb 5;16:1536023. doi: 10.3389/fphar.2025.1536023. eCollection 2025.
Plant active substances are extensively utilized in treating rheumatoid arthritis (RA). Despite numerous experimental and clinical studies on plant active substances their efficacy remains largely unsubstantiated. The widespread use of these extracts as therapeutic measures for RA is problematic due to the lack of compelling evidence.
Our research aims to assess the impact of plant active substances on RA by conducting a network meta-analysis.
We systematically searched four electronic databases-PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, and Web of Science-from their inception to August 2024. The main focus was on assessing primary outcomes, including the Visual Analogue Scale (VAS), inflammatory markers, Swollen Joint Count (SJC), Tender Joint Count (TJC), and Disease Activity Score on 28 joints (DAS28). We performed data analysis using StataMP 15.1 software and ranked the therapeutic effects based on the Surface Under the Cumulative Ranking Curve (SUCRA) probability values.
Based on screening procedures, 18 eligible studies were incorporated into the analysis. These studies encompassed a total of 1,674 RA patients and investigated 10 different plant active substance therapies. Specifically, 10 studies included VAS indicators, 17 studies included inflammatory marker indicators, 14 studies included DAS28 indicators, 13 studies included SJC indicators, and 13 studies included TJC indicators. Based on SUCRA values, quercetin appeared to be the most effective treatment for decreasing serum VAS levels (67.3%). Furthermore, curcumin emerged as the most promising option for reducing inflammatory marker levels (72.3%), SJC (75.6%), and TJC (76.2%). Lastly, with respect to DAS28, resveratrol emerged as the optimal choice (74.3%).
According to the network meta-analysis (NMA), curcumin exhibited superior efficacy compared to placebo in decreasing SJC and TJC. Additionally, curcumin demonstrated greater effectiveness in reducing inflammatory markers. Quercetin was more effective in reducing VAS, and resveratrol was more effective in reducing DAS28. Patients with RA may benefit from these findings. Insightful information from this study is helpful for RA patients to consider using plant active substance therapies. For their efficacy and safety to be confirmed, more proof is needed.
植物活性物质被广泛用于治疗类风湿关节炎(RA)。尽管对植物活性物质进行了大量实验和临床研究,但其疗效在很大程度上仍未得到证实。由于缺乏确凿证据,将这些提取物广泛用作RA的治疗措施存在问题。
我们的研究旨在通过进行网络荟萃分析来评估植物活性物质对RA的影响。
我们系统地检索了四个电子数据库——PubMed、EMBASE、Cochrane对照试验中央注册库和Web of Science,检索时间从各数据库建库至2024年8月。主要重点是评估主要结局,包括视觉模拟量表(VAS)、炎症标志物、肿胀关节计数(SJC)、压痛关节计数(TJC)和28个关节的疾病活动评分(DAS28)。我们使用StataMP 15.1软件进行数据分析,并根据累积排序曲线下面积(SUCRA)概率值对治疗效果进行排名。
基于筛选程序,18项符合条件的研究被纳入分析。这些研究共纳入了1674例RA患者,并调查了10种不同的植物活性物质疗法。具体而言,10项研究包括VAS指标,17项研究包括炎症标志物指标,14项研究包括DAS28指标,13项研究包括SJC指标,13项研究包括TJC指标。基于SUCRA值,槲皮素似乎是降低血清VAS水平最有效的治疗方法(67.3%)。此外,姜黄素是降低炎症标志物水平(72.3%)、SJC(75.6%)和TJC(76.2%)最有前景的选择。最后,就DAS28而言,白藜芦醇是最佳选择(74.3%)。
根据网络荟萃分析(NMA),姜黄素在降低SJC和TJC方面比安慰剂表现出更好的疗效。此外,姜黄素在降低炎症标志物方面显示出更大的有效性。槲皮素在降低VAS方面更有效,白藜芦醇在降低DAS28方面更有效。RA患者可能会从这些发现中受益。本研究的深刻信息有助于RA患者考虑使用植物活性物质疗法。要确认其疗效和安全性,还需要更多证据。